ICLR Key Statistics, Chart & Performance
The current stock price of ICLR is 185 USD. In the past month the price increased by 11.9%. In the past year, price decreased by -12.01%.
ICLR Latest News, Press Relases and Analysis
ICLR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.38 | 221.98B | ||
| DHR | DANAHER CORP | 29.41 | 160.19B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 186.73 | 56.74B | ||
| A | AGILENT TECHNOLOGIES INC | 27.51 | 43.52B | ||
| IQV | IQVIA HOLDINGS INC | 19.78 | 39.17B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.29 | 30.17B | ||
| WAT | WATERS CORP | 31.77 | 24.02B | ||
| ILMN | ILLUMINA INC | 30.15 | 20.09B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.21 | 19.95B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.43 | 16.69B | ||
| TEM | TEMPUS AI INC | N/A | 13.86B | ||
| RVTY | REVVITY INC | 21.8 | 11.84B |
Related stock screener links
About ICLR
Company Profile
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The company is headquartered in Dublin, Dublin and currently employs 39,900 full-time employees. The firm is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. The company offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The firm's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. The company also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
Company Info
ICON PLC
South County Business Park, LEOPARDSTOWN, Dublin 18
DUBLIN DUBLIN 00000 IE
CEO: Steve Cutler
Employees: 39900
Phone: 35312912000
ICON PLC / ICLR FAQ
Can you describe the business of ICON PLC?
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The company is headquartered in Dublin, Dublin and currently employs 39,900 full-time employees. The firm is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. The company offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The firm's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. The company also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
What is the stock price of ICON PLC today?
The current stock price of ICLR is 185 USD. The price increased by 0.74% in the last trading session.
What is the dividend status of ICON PLC?
ICLR does not pay a dividend.
How is the ChartMill rating for ICON PLC?
ICLR has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How many employees does ICON PLC have?
ICON PLC (ICLR) currently has 39900 employees.
What is the Short Interest ratio of ICON PLC (ICLR) stock?
The outstanding short interest for ICON PLC (ICLR) is 2.44% of its float.
ICLR Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ICLR. When comparing the yearly performance of all stocks, ICLR is a bad performer in the overall market: 66.29% of all stocks are doing better.
ICLR Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ICLR. ICLR has only an average score on both its financial health and profitability.
ICLR Financial Highlights
Over the last trailing twelve months ICLR reported a non-GAAP Earnings per Share(EPS) of 13.19. The EPS decreased by -5.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 7.4% | ||
| ROA | 3.63% | ||
| ROE | 6.42% | ||
| Debt/Equity | 0.31 |
ICLR Forecast & Estimates
24 analysts have analysed ICLR and the average price target is 209.8 USD. This implies a price increase of 13.41% is expected in the next year compared to the current price of 185.
For the next year, analysts expect an EPS growth of -4.67% and a revenue growth -2.45% for ICLR